期刊文献+
共找到664篇文章
< 1 2 34 >
每页显示 20 50 100
强心宁煎剂治疗慢性心力衰竭(非保留型)的有效性及安全性系统评价与Meta分析 被引量:4
1
作者 韩美子 《世界中医药》 CAS 2019年第10期2640-2646,共7页
目的:通过循证医学方法评价中药复方强心宁煎剂治疗慢性心力衰竭(非保留型)的有效性及安全性。方法:系统检索中文数据库cnki数据库、万方数据库、维普数据库、sinomed数据库,英文数据库pubmed、medline数据库及corchrane library。文献... 目的:通过循证医学方法评价中药复方强心宁煎剂治疗慢性心力衰竭(非保留型)的有效性及安全性。方法:系统检索中文数据库cnki数据库、万方数据库、维普数据库、sinomed数据库,英文数据库pubmed、medline数据库及corchrane library。文献检索年限起始为不限至2018年3月,分别以“强心宁”及qiangxinning作为关键词全文检索中英文数据库。纳入强心宁煎剂加标准治疗对照标准治疗治疗慢性心力衰竭的RCT文献。采用corchrane handbook评价偏倚,并采用review manage 5.3对计量资料进行Meta分析;对异质性采用敏感性分析,并做合理解释;发表偏倚采用倒漏斗图进行评估。结果:共纳入10项RCT研究752例患者,文章质量风险评估普遍为Unclear risk of bias,观察组比较对照组,疗效结果显示:有效率RD(95%CI):2.5[0.82-8.39],heterogeneity:P=0.95;左室射血分数(LVEF):MD(95%CI):0.60[0.35-0.85],heterogeneity:P=0.19;左心室舒张末期内径(LVEDD):MD(95%CI):-0.48[-0.78至-0.17],heterogeneity:P=021。结论:强心宁煎剂对射血分数减低型心力衰竭的能够减轻心力衰竭患者的临床症状,且能在一定程度上提升射血分数,减低左室舒张期末径,出现的不良较少,疗效性及安全性仍需强证据等级研究进一步证实。 展开更多
关键词 强心宁 慢性心力衰竭 系统评价 疗效 META分析 射血分数减低 射血分数中等 安全性
下载PDF
强心宁治疗阳虚水泛型心衰26例
2
作者 王明媛 刘彤 《实用中医内科杂志》 2011年第8期43-44,共2页
[目的]观察强心宁治疗阳虚水泛型心衰疗效。[方法]将50例随机分为两组,对照组24例应用洋地黄制剂、利尿剂、ACEI、ARB、硝酸酯类等常规治疗;治疗组26例在控制并发症的基础上予强心宁50mL日3次口服,疗程均为4周。[结果]治疗组显效5例,好... [目的]观察强心宁治疗阳虚水泛型心衰疗效。[方法]将50例随机分为两组,对照组24例应用洋地黄制剂、利尿剂、ACEI、ARB、硝酸酯类等常规治疗;治疗组26例在控制并发症的基础上予强心宁50mL日3次口服,疗程均为4周。[结果]治疗组显效5例,好转18例,无效3例,总有效率88.45%,无不良反应。对照组显效6例,好转16例,无效2例,总有效率91.67%,有10例次出现不良反应。[结论]强心宁既具有强心、利尿、扩血管及逆转心室重构作用,又具有利尿而不失离子、无毒副反应、安全有效、价格低廉、患者依从性好等优点,成为中医药治疗心衰的重要手段,值得推广应用。 展开更多
关键词 心衰 阳虚水泛 强心宁 洋地黄 利尿剂 ACEI ARB 硝酸酯 杨积武 中医药治疗
下载PDF
强心宁煎剂对慢性心力衰竭心肾阳(气)虚、血瘀水停证患者血浆TNF-α,IL-6的影响 被引量:10
3
作者 王祺 杨积武 《中国实验方剂学杂志》 CAS 北大核心 2011年第14期264-266,共3页
目的:探讨强心宁煎剂对慢性心力衰竭(CHF)患者血浆肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)的影响。方法:将68例CHF患者随机分为治疗组和对照组(每组34例),治疗组在对照组常规西药治疗基础上加用强心宁煎剂。2组于治疗前后分别测... 目的:探讨强心宁煎剂对慢性心力衰竭(CHF)患者血浆肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)的影响。方法:将68例CHF患者随机分为治疗组和对照组(每组34例),治疗组在对照组常规西药治疗基础上加用强心宁煎剂。2组于治疗前后分别测定血浆TNF-α,IL-6水平,同时评估NYHA心功能分级。结果:治疗后2组NYHA心功能分级均较同组治疗前改善(P<0.05),且治疗组优于对照组(P<0.05);同时治疗组血浆TNF-α,IL-6水平明显下降,与对照组及同组治疗前比较差异显著(P<0.05)。结论:强心宁煎剂能够降低CHF患者血浆TNF-α,IL-6水平,可作为治疗CHF有效药物之一。 展开更多
关键词 强心宁煎剂 慢性心力衰竭 血浆肿瘤坏死因子-Α 白细胞介素-6
原文传递
心肾阳虚型慢性心衰病机及证治 被引量:7
4
作者 傅健 王凤荣 《实用中医内科杂志》 2013年第4期72-74,共3页
根据慢性心衰临床症状与中医的心悸、喘证、痰饮、水肿、胸痹五个证型的病因,阐述经方(真武汤、苓桂术甘汤、参附汤、强心宁煎剂)论治心肾阳虚型心衰病。
关键词 慢性心衰 心肾阳虚 心悸 喘证 痰饮 水肿 胸痹 真武汤 苓桂术甘汤 参附汤 强心宁煎剂 伤寒论 妇人良方
下载PDF
杨积武治疗心衰病的经验总结 被引量:5
5
作者 王蕊 杨莺 《辽宁中医杂志》 CAS 2022年第2期15-18,共4页
心力衰竭(心衰)是心系疾病发展的终末阶段,其有较高的病死率和住院率。心衰是心功能不全,心室排出血量不能满足需求,器官组织缺血缺氧导致一系列症状的临床综合征。杨积武教授是我国著名心血管病专家,国家第四批、第五批老中医药专家学... 心力衰竭(心衰)是心系疾病发展的终末阶段,其有较高的病死率和住院率。心衰是心功能不全,心室排出血量不能满足需求,器官组织缺血缺氧导致一系列症状的临床综合征。杨积武教授是我国著名心血管病专家,国家第四批、第五批老中医药专家学术经验继承工作指导教师。杨老在中医基础理论及临床实践方面有高深的造诣,继承前人经验,师古而不泥古,敢于实践,勇于创新;杨教授创立了自己独特的“本于心,精于五脏论治、尤重脾肾阴阳”的中医心病学术思想体系。杨老指出虚、瘀、水贯穿心衰病的始终,是心衰病的基本病机,心衰治疗原则始终围绕益气温阳,活血利水,根据心衰病的主要病因病机、治则治法,研制出“强心宁”煎剂,应用于临床,取得疗效显著。 展开更多
关键词 中西医结合 心衰病 强心宁 经验总结 杨积武
下载PDF
强心宁煎剂联合曲美他嗪对慢性心衰左心室功能及血浆心钠素和内皮素水平的影响 被引量:5
6
作者 白延平 刘智娜 高燕 《四川中医》 2016年第9期69-71,共3页
目的:观察强心宁煎剂联合曲美他嗪对慢性心衰左心室功能及血浆心钠素、内皮素水平的影响。方法:选取2013年2月~2015年1月我院心内科收治的62例慢性心衰患者为研究对象,随机数字表法分为研究组和对照组各31例,对照组给予强心宁煎剂治疗... 目的:观察强心宁煎剂联合曲美他嗪对慢性心衰左心室功能及血浆心钠素、内皮素水平的影响。方法:选取2013年2月~2015年1月我院心内科收治的62例慢性心衰患者为研究对象,随机数字表法分为研究组和对照组各31例,对照组给予强心宁煎剂治疗,研究组在对照组基础上另联合曲美他嗪治疗,对两组治疗后临床疗效、左心室功能[左心室射血分数(LVEF)、左室舒张末期内径(LVDd)、左室收缩末期容量(LVESV)]、血浆心钠素(ANP)、血浆内皮素(ET)及药物不良反应进行观察比较。结果:两组治疗后研究组临床总有效率87.10%较对照组62.07%显著高(P〈0.05);两组治疗后LVEF较治疗前显著升高,LVDd、LVESV显著下降,且治疗后研究组LVEF较对照组升高显著,LVDd、LVESV降低显著,均具有统计学意义(P〈0.05);两组治疗后ANP、ET分别均较治疗前降低,仅ANP治疗前后有显著差异(P〈0.05),且治疗后研究组ANP、ET分别均较对照组降低显著,均具有统计学意义(P〈0.05);两组药物不良反应比较无显著差异(P〉0.05)。结论:强心宁煎剂联合曲美他嗪对慢性心衰患者具有较好的临床疗效,且对左心室功能、血浆心钠素、内皮素水平均具有显著改善作用。 展开更多
关键词 慢性心衰 强心宁煎剂 曲美他嗪 左心室功能 血浆心钠素 内皮素
下载PDF
自拟强心宁方联合沙库巴曲缬沙坦治疗慢性心力衰竭阳虚水泛证的效果观察 被引量:1
7
作者 朱改针 刘会君 +1 位作者 胡冰 赵保昌 《中国实用医刊》 2023年第14期116-119,共4页
目的探讨自拟强心宁方联合沙库巴曲缬沙坦钠治疗慢性心力衰竭(CHF)阳虚水泛证的临床疗效。方法抽取2020年1月至2022年9月解放军陆军第八十三集团军医院收治的86例阳虚水泛证CHF患者,采用随机数字表法分为对照组与观察组,每组43例。对照... 目的探讨自拟强心宁方联合沙库巴曲缬沙坦钠治疗慢性心力衰竭(CHF)阳虚水泛证的临床疗效。方法抽取2020年1月至2022年9月解放军陆军第八十三集团军医院收治的86例阳虚水泛证CHF患者,采用随机数字表法分为对照组与观察组,每组43例。对照组采用沙库巴曲缬沙坦治疗,观察组在对照组基础上加用自拟强心宁方治疗,均持续治疗3个月。比较两组的临床疗效、中医证候评分、心功能及6 min步行距离(6MWD)。结果观察组临床总有效率(93.02%,40/43)高于对照组(76.74%,33/43),中医证候评分[(7.60±1.71)分]低于对照组[(10.23±2.09)分],P<0.05;治疗3个月时,观察组左室射血分数高于对照组,左心室收缩末期内径、左心室舒张末期内径低于对照组(P<0.05);治疗3个月时,观察组6MWD高于对照组(P<0.05)。结论自拟强心宁方联合沙库巴曲缬沙坦钠治疗阳虚水泛证CHF患者可提高治疗效果,减轻临床症状,改善心功能及6MWD。 展开更多
关键词 心力衰竭 阳虚水泛证 沙库巴曲缬沙坦 自拟强心宁方
原文传递
强心宁煎剂治疗扩张型心肌病临床观察 被引量:3
8
作者 吕洋 陈岩 杨积武 《辽宁中医药大学学报》 CAS 2015年第6期201-203,共3页
目的:观察强心宁煎剂治疗扩张型心肌病的临床疗效。方法:将76例扩张型心肌病患者随机分为观察组和对照组各38例。两组均限制钠盐摄入,合理应用强心剂、利尿剂、β受体阻滞剂、血管紧张素转换酶抑制剂(ACEI)、营养心肌药物、硝酸脂类以... 目的:观察强心宁煎剂治疗扩张型心肌病的临床疗效。方法:将76例扩张型心肌病患者随机分为观察组和对照组各38例。两组均限制钠盐摄入,合理应用强心剂、利尿剂、β受体阻滞剂、血管紧张素转换酶抑制剂(ACEI)、营养心肌药物、硝酸脂类以及控制感染等方法,观察组在常规西医治疗的基础上同时加服强心宁煎剂,4个疗程后比较疗效。结果:观察组总有效率92.11%,高于对照组的86.84%,两组差异有统计学意义(P<0.05);两组患者治疗后左心室舒张末期内径(LVED)明显下降,且左心室射血分数(LVEF)显著上升,与治疗前相比差异均具有统计学意义(P<0.05);治疗后两组组间比较,观察组左心室舒张末期内径(LVED)小于对照组,且左心室射血分数(LVEF)高于对照组,差异有统计学意义(P<0.05)。结论:强心宁煎剂治疗扩张型心肌病疗效确切,能明显改善患者心脏功能,减轻临床症状,提高生活质量,延长生命,且优于单纯西药治疗。 展开更多
关键词 强心宁煎剂 扩张型心肌病 心功能 中西医结合
下载PDF
杨积武教授治疗慢性心力衰竭经验集萃 被引量:2
9
作者 段盈竹 于睿 杨积武 《辽宁中医药大学学报》 CAS 2016年第4期101-103,共3页
杨积武教授长期从事心血管疾病的临床治疗及实验研究,对慢性心力衰竭的治疗有独特的见解,并且积累了临床丰富的经验,总结了一套辨证施治的治疗方法并取得良好疗效。真诚的希望将杨师临床治疗心衰的经验推广,更好指导医生在临床中对心衰... 杨积武教授长期从事心血管疾病的临床治疗及实验研究,对慢性心力衰竭的治疗有独特的见解,并且积累了临床丰富的经验,总结了一套辨证施治的治疗方法并取得良好疗效。真诚的希望将杨师临床治疗心衰的经验推广,更好指导医生在临床中对心衰的认识和治疗。 展开更多
关键词 杨积武 慢性心衰 强心宁煎剂 经验
下载PDF
Effect of Qiangxin Fumai Granule(强心复脉颗粒) on Electrophysiological Functions of the Sinoatrial Node during Ischemia-reperfusion of the Right Coronary Artery in Rabbits 被引量:5
10
作者 刘如秀 谭双 +2 位作者 刘志明 王阶 王彦云 《Chinese Journal of Integrative Medicine》 SCIE CAS 2008年第3期202-206,共5页
Objective: To study the effect of the Chinese medicine Qiangxin Fumai Granule (强心复脉颗粒, QFG) on electrophysiological functions of the sinoatrial node during ischemia-reperfusion (IR) of the right coronary ar... Objective: To study the effect of the Chinese medicine Qiangxin Fumai Granule (强心复脉颗粒, QFG) on electrophysiological functions of the sinoatrial node during ischemia-reperfusion (IR) of the right coronary artery in rabbits. Methods: The right coronary artery IR model in rabbits was adopted. The modeled rabbits were randomly divided into 4 groups: the model group, the atropine group, the highdose QFG group, and the low-dose QFG group, with 8 animals in each group. In addition, twelve rabbits were selected for the sham-operative group. The drugs were administered once via duodenal perfusion after modeling had been stabilized for 10 min. The changes in AA interval, the sinoatrial conduction time (SACT), the sinus node recovery time (SNRT), the corrected sinus node recovery time (CSNRT) and the index of sinus node recovery time (ISNRT) at different time points during ischemia and reperfusion were measured. Results: The AA interval was prolonged for more than 40 ms in the model group during ischemia. Compared with the model group, the four electrophysiological parameters abovementioned in the high-dose QFG group and the low-dose QFG group were decreased to different extents at each time point (P〈0.01 or P〈0.05), and no statistically significant differences were found between the QFG groups and the atropine group (P〉0.05). Conclusion: QFG is beneficial for accelerating the recovery of sinus node autorhythmicity and conduction function, so as to protect electrophysiological functions of the sinoatrial node. Accelerating the recovery of autorhythmicity and conduction function in the sinus node is considered its electrophysiological mechanism in the treatment of sinoatrial node injury induced by ischemia. 展开更多
关键词 qiangxin Fumai Granule ISCHEMIA-REPERFUSION sinoatrial node function
原文传递
Effect of Qiangxin Huoli decoction on rats with adriamycin-induced chronic heart failure 被引量:4
11
作者 Gao Ling Yang Ting +3 位作者 Zhu Jiaqi Xu Lei Su Li Wang Di 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2019年第1期81-88,共8页
OBJECTIVE: To investigate the effect of Qiangxin Huoli decoction on rats with chronic heart failure(CHF) induced by adriamycin(ADR), and to investigate the underlying mechanism of this effect.METHODS: Ninety-six healt... OBJECTIVE: To investigate the effect of Qiangxin Huoli decoction on rats with chronic heart failure(CHF) induced by adriamycin(ADR), and to investigate the underlying mechanism of this effect.METHODS: Ninety-six healthy Wistar rats were divided into six groups: control, CHF model, CHF treated by Shenfu injection, and three CHF groups treated with Qiangxin Huoli decoction at high, medium, and low doses, respectively. Qiangxin Huoli decoction was administered orally to protect the stomach in the three Qiangxin Huoli decoction groups, while the control group and the CHF model group were administered the same volume of 0.9% physiological saline, and the Shenfu group wereadministered the same volume of Shenfu injection. Ten days later, the CHF model was then induced in all groups except the control group by intraperitoneal injection of ADR at gradient dose intervals. The bodyweights were recorded on days 10, 20, 30, and 40. Hemodynamic indices were recorded, including left ventricular systolic pressure(LVSP), left ventricular end-diastolic pressure(LVEDP), maximum increase in left ventricular pressure(+dp/dt_(max)), maximum decrease in left ventricular pressure(-dp/dt_(max)), heart rate(HR), and electrocardiogram using an eight-channel physiological recorder with LabChart software monitoring. The plasma brain natriuretic peptide(BNP) concentration was determined by enzyme-linked immunosorbent adsorption. The expressions of B-cell lymphoma-2(Bcl-2) and Bcl-2-associated X protein(Bax) were detected by immunohistochemical methods.RESULTS: The CHF model group were in poor condition, and the mean bodyweight was significantly decreased compared with the control group. Furthermore, compared with the control group, the CHF groups had significantly decreased LVSP, +dp/dt_(max), and-dp/dt_(max), and significantly increased LVEDP. The CHF groups also showed significant increases in HR, S-T segment elevation, and plasma BNP levels compared with the control group. Compared with the CHF model group, the treatment groups had signifi 展开更多
关键词 Heart failure HEMODYNAMICS DOXORUBICIN NATRIURETIC peptide brain Genes bcl-2 Bcl-2associated X protein qiangxin Huoli DECOCTION
原文传递
Mechanism of Qili Qiangxin Capsule for Heart Failure Based on miR133a-Endoplasmic Reticulum Stress
12
作者 JI Xiao-di YANG Ding +5 位作者 CUI Xi-yuan LOU Li-xia NIE Bo ZHAO Jiu-li ZHAO Ming-jing WU Ai-ming 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2024年第5期398-407,共10页
Objective:To investigate the pharmacological mechanism of Qili Qiangxin Capsule(QLQX)improvement of heart failure(HF)based on miR133a-endoplasmic reticulum stress(ERS)pathway.Methods:A left coronary artery ligation-in... Objective:To investigate the pharmacological mechanism of Qili Qiangxin Capsule(QLQX)improvement of heart failure(HF)based on miR133a-endoplasmic reticulum stress(ERS)pathway.Methods:A left coronary artery ligation-induced HF after myocardial infarction model was used in this study.Rats were randomly assigned to the sham group,the model group,the QLQX group[0.32 g/(kg·d)],and the captopril group[2.25 mg/(kg·d)],15 rats per group,followed by 4 weeks of medication.Cardiac function such as left ventricular ejection fraction(EF),fractional shortening(FS),left ventricular systolic pressure(LVSP),left ventricular end diastolic pressure(LVEDP),the maximal rate of increase of left ventricular pressure(+dp/dt max),and the maximal rate of decrease of left ventricular pressure(–dp/dt max)were monitored by echocardiography and hemodynamics.Hematoxylin and eosin(HE)and Masson stainings were used to visualize pathological changes in myocardial tissue.The m RNA expression of mi R133a,glucose-regulated protein78(GRP78),inositol-requiring enzyme 1(IRE1),activating transcription factor 6(ATF6),X-box binding protein1(XBP1),C/EBP homologous protein(CHOP)and Caspase 12 were detected by RT-PCR.The protein expression of GRP78,p-IRE1/IRE1ratio,cleaved-ATF6,XBP1-s(the spliced form of XBP1),CHOP and Caspase 12 were detected by Western blot.Td T-mediated d UTP nick-end labeling(TUNEL)staining was used to detect the rate of apoptosis.Results:QLQX significantly improved cardiac function as evidenced by increased EF,FS,LVSP,+dp/dt max,-dp/dt max,and decreased LVEDP(P<0.05,P<0.01).HE staining showed that QLQX ameliorated cardiac pathologic damage to some extent.Masson staining indicated that QLQX significantly reduced collagen volume fraction in myocardial tissue(P<0.01).Results from RT-PCR and Western blot showed that QLQX significantly increased the expression of mi R133a and inhibited the m RNA expressions of GRP78,IRE1,ATF6 and XBP1,as well as decreased the protein expressions of GRP78,cleaved-ATF6 and XBP1-s and decreased p-IRE1/IRE1 展开更多
关键词 heart failure Qili qiangxin Capsule miR133a endoplasmic reticulum stress APOPTOSIS
原文传递
Qili Qiangxin, a compound herbal medicine formula, alleviates hypoxia-reoxygenation-induced apoptotic and autophagic cell death via suppression of ROS/AMPK/mTOR pathway in vitro 被引量:4
13
作者 Cai-lian Fan Wan-jun Cai +2 位作者 Meng-nan Ye Miao Chen Yi Dai 《Journal of Integrative Medicine》 SCIE CAS CSCD 2022年第4期365-375,共11页
Objective: Qili Qiangxin(QLQX), a compound herbal medicine formula, is used effectively to treat congestive heart failure in China. However, the molecular mechanisms of the cardioprotective effect are still unclear. T... Objective: Qili Qiangxin(QLQX), a compound herbal medicine formula, is used effectively to treat congestive heart failure in China. However, the molecular mechanisms of the cardioprotective effect are still unclear. This study explores the cardioprotective effect and mechanism of QLQX using the hypoxiareoxygenation(H/R)-induced myocardial injury model.Methods: The main chemical constituents of QLQX were analyzed using high-performance liquid chromatography-evaporative light-scattering detection. The model of H/R-induced myocardial injury in H9c2 cells was developed to simulate myocardial ischemia–reperfusion injury. Apoptosis, autophagy,and generation of reactive oxygen species(ROS) were measured to assess the protective effect of QLQX. Proteins related to autophagy, apoptosis and signalling pathways were detected using Western blotting.Results: Apoptosis, autophagy and the excessive production of ROS induced by H/R were significantly reduced after treating the H9c2 cells with QLQX. QLQX treatment at concentrations of 50 and 250 μg/mL caused significant reduction in the levels of LC3Ⅱ and p62 degradation(P < 0.05), and also suppressed the AMPK/mTOR signalling pathway. Furthermore, the AMPK inhibitor Compound C(at 0.5 μmol/L),and QLQX(250 μg/mL) significantly inhibited H/R-induced autophagy and apoptosis(P < 0.01), while AICAR(an AMPK activator, at 0.5 mmol/L) increased cardiomyocyte apoptosis and autophagy and abolished the anti-apoptotic effect of QLQX. Similar phenomena were also observed on the expressions of apoptotic and autophagic proteins, demonstrating that QLQX reduced the apoptosis and autophagy in the H/R-induced injury model via inhibiting the AMPK/mTOR pathway. Moreover, ROS scavenger,N-Acetyl-L-cysteine(NAC, at 2.5 mmol/L), significantly reduced H/R-triggered cell apoptosis and autophagy(P < 0.01). Meanwhile, NAC treatment down-regulated the ratio of phosphorylation of AMPK/AMPK(P < 0.01), which showed a similar effect to QLQX.Conclusion: QLQX plays a cardioprotective role by alleviating apop 展开更多
关键词 Herbal medicine Qili qiangxin formula Hypoxia–reoxygenation Reactive oxygen species Autophagy Apoptosis AMPK/mTOR pathway
原文传递
Efficacy and safety of oral Chinese patent medicine combined with sacubitril/valsartan in the treatment of chronic heart failure:A Metaanalysis
14
作者 TAO Shi-yi TANG Xian-wen +6 位作者 ZHANG Lan-xin YU Lin-tong ZHANG Jin YANG Deshuang LI Ling-ling HUANG Li WU Jia-yun 《Journal of Hainan Medical University》 CAS 2023年第16期52-60,共9页
Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Coch... Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Cochrane Library and EMbase were retrieved to screen out randomized controlled trials Chinese patent medicine and Western medicine in treating CHF.Manual retrieval was also applied as a supplement.The Cochrane Reviewers Handbook 5.1.0 was used to evaluate the bias risk of the included studies and RevMan 5.4 software was used for Meta-analysis.Results:A total of 1301 patients enrolled in the 13 RCTs were included.According to the results of Meta-analysis,a combination of oral Chinese patent medicine and sacubitril/valsartan could further improve total effectiveness rate(RR=1.23,95%CI[1.16,1.30],P<0.001),increase 6 minutes’walk distance(MD=53.04,95%CI[33.43,72.64],P<0.001),improve left ventricular ejection fraction(MD=6.67,95%CI[5.15,8.19],P<0.001)and stroke volume(MD=7.56,95%CI[3.94,11.18],P<0.001),reduce left ventricular end-diastolic dimension(MD=-3.68,95%CI[-4.57,-2.78],P<0.001)and N terminal pro B type natriuretic peptide(MD=-434.08,95%CI[-518.95,-349.22],P<0.001)and no statistically significant difference in drug safety was found between the sacubitril/valsartan-only group and the combined treatment group(RR=0.73,95%CI[0.32,1.65],P=0.45).Conclusion:It’s indicated that a combination of traditional Chinese patent medicine and sacubitril/valsartan had a good clinical efficacy in the treatment of CHF,which had certain guiding significance for clinical practice. 展开更多
关键词 Oral Chinese patent medicine Sacubitril/valsartan Angiotensin receptor-neprilysin inhibitor Chronic heart failure Qili qiangxin Capsule Qishen Yiqi Pill Dengzhan Shengmai Capsule
下载PDF
Protective Role of Wumen Jianzhong Qiangxin Granules in Rats with Post-myocardial Infarction Heart Failure and Effect on Myocardial Energy Metabolism
15
作者 Hongfeng WAN Rongqi BAO +1 位作者 Guoqiang LIANG Xiaoqing YANG 《Medicinal Plant》 CAS 2023年第2期69-73,共5页
[Objectives]The paper was to determine the effect of Wumen Jianzhong Qiangxin granules(WJQG)on myocardial energy metabolism in a chronic heart failure rat model after myocardial infarction(MI).[Methods]Totally 40 norm... [Objectives]The paper was to determine the effect of Wumen Jianzhong Qiangxin granules(WJQG)on myocardial energy metabolism in a chronic heart failure rat model after myocardial infarction(MI).[Methods]Totally 40 normal male SD rats were randomly divided into sham operation group,model group,trimetazidine group and WJQG group(n=10).The model of MI was established by ligation of the left anterior descending branch except sham operation group.The rats in trimetazidine and WJQG groups were gavaged with 60 mg/kg and 16 g/kg emodin daily,respectively.After administration for 4 weeks,the changes in heart rate(HR),R-R interval(RRI),systolic arterial pressure(SAP),diastolic arterial pressure(DAP),mean arterial pressure(MAP),pulse pressure(PP),left ventricular end-diastolic pressure(LVEDP),rates of maximum positive left ventricular pressure development(+dp/dtmax)and rates of maximum negative left ventricular pressure development(-dp/dtmax)were analyzed.Morphology of myocardial tissues was observed by HE staining,the levels of myocardial tissue adenosine triphosphate(ATP)and glucose transporter type 4(GLUT-4)were determined using scientific research kit,and the expressions of mitochondrial creatine kinase(mit-CK),creatine kinase MM isoenzyme(CK-MM)and adenine nucleotide translocator(ANT)in myocardial tissues were determined by Western blotting.[Results](i)Compared with sham group,LVEDP obviously increased,while+dp/dtmax and-dp/dtmax significantly decreased in model group,with extremely significant difference in statistics(P<0.01).Compared with model group,LVEDP decreased,while+dp/dtmax and-dp/dtmax increased in trimetazidine group and WJQG group,with significant difference in statistics(P<0.05 orP<0.01).(ii)The cardiomyocytes ultrastructure of rats in sham group was normal,while in model group,extensive focus of MI can be seen under optic microscope.In the infarction focus,we can see outline of the necrotic tissue,infiltration of inflammatory cells,few fibroblasts,as well as the slow growth of granulation tissue.Focus of M 展开更多
关键词 Wumen Jianzhong qiangxin granules Heart failure Cardiac function Energy metabolism Myocardial energy shuttle
下载PDF
Echocardiographic Evaluation of Qiangxin Decoction Combined with Cardiac Resynchronization Therapy for Patients with Chronic Heart Failure
16
作者 Wei Yunfeng Guo Daoning +1 位作者 Zou Xiaopan Ding Qian 《World Journal of Integrated Traditional and Western Medicine》 2019年第3期7-11,共5页
OBJECTIVE: To explore the echocardiographic evaluation of patients with chronic heart failure (CHF) after Qiangxin Decoction combined with cardiac resynchronization therapy. METHODS: A total of 140 CHF patients admitt... OBJECTIVE: To explore the echocardiographic evaluation of patients with chronic heart failure (CHF) after Qiangxin Decoction combined with cardiac resynchronization therapy. METHODS: A total of 140 CHF patients admitted to our hospital were randomly divided into combined group (Qiangxin Decoction and cardiac resynchronization, n = 70) and routine group (cardiac resynchronization, n = 70), and they were treated for 2 courses (16 weeks), with 8 weeks as a course. The improvement of heart function classification (HYHA) was observed before and after treatment, and the therapeutic effects were evaluated according to the improvement of heart function classification (markedly effective, effective, invalid, and worsening). The traditional Chinese medicine (TCM) diagnostic criteria was the main symptoms (0 to 6 points), secondary symptoms (0 to 3 points), tongue picture (0 to 1 point) and pulse condition (0 to 1 point), and the higher the score was, the more obvious the symptoms were. The left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF) and cardiac output (CO) were observed and recorded according to the heart color ultrasound before and after treatment. And the Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used to evaluate the life quality before and after treatment, and the highest score of the scale was 105 points. The higher the score was, the obvious the symptoms were, and the worse the life quality was. And the adverse reactions were recorded in the 2 groups. RESULTS: After the treatment, the total effective rate in the routine group was significantly lower than that in the combined group (75.71% vs . 94.30%), and there was statistically significant difference (P < 0.05). After the treatment, the TCM syndrome score in the routine group was higher than that in the combined group ((14.37±3.59) points vs.(10.53±3.11) points), and there was statistically significant difference (P < 0.05). After the treatment, the l 展开更多
关键词 qiangxin DECOCTION CARDIAC RESYNCHRONIZATION therapy Chronic heart failure ECHOCARDIOGRAM TCM syndrome SCORE
下载PDF
Treatment of Dilated Cardiomyopathy with Qilan Qiangxin Capsule Combined with Sakubatra and Valsartan: A Case Report
17
作者 Tong Li Cuiying Zhang 《Journal of Advances in Medicine Science》 2020年第1期32-37,共6页
A case of dilated cardiomyopathy was reported,including the course of onset and long-term application of Qilan Qiangxin Capsule combined with a new anti-heart failure drug,Sakubatril Valsartan,in order to improve the ... A case of dilated cardiomyopathy was reported,including the course of onset and long-term application of Qilan Qiangxin Capsule combined with a new anti-heart failure drug,Sakubatril Valsartan,in order to improve the symptoms of heart failure,increase the LVEF(left ventricular ejection fraction),and reduce the plasma NT-proBNP(N-terminal B-type natriuretic peptide)level.The effect of improving ventricular remodeling is obvious,and the quality of life of patients is improved. 展开更多
关键词 DILATED CARDIOMYOPATHY Sakubatril VALSARTAN Qilan qiangxin CAPSULE
下载PDF
芪苈强心胶囊对冠心病合并心力衰竭患者血清脂联素水平及心功能的影响 被引量:72
18
作者 李强 郭壮波 +1 位作者 黎庆梅 郭顺华 《中国病理生理杂志》 CAS CSCD 北大核心 2014年第6期1119-1122,共4页
目的:探讨芪苈强心胶囊对冠心病合并心力衰竭患者血清脂联素(APN)、氨基末端脑钠肽前体(NT-proBNP)水平及心功能的影响。方法:将120例冠心病合并心力衰竭患者随机分为对照组和治疗组,在西医常规治疗基础上分别加用对照胶囊和芪苈强心胶... 目的:探讨芪苈强心胶囊对冠心病合并心力衰竭患者血清脂联素(APN)、氨基末端脑钠肽前体(NT-proBNP)水平及心功能的影响。方法:将120例冠心病合并心力衰竭患者随机分为对照组和治疗组,在西医常规治疗基础上分别加用对照胶囊和芪苈强心胶囊,疗程6个月。观察治疗前后患者的心功能分级,超声心动图下测定左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)和左心室射血分数(LVEF),测量患者6 min步行距离(6-MWT),酶联免疫法测定血清APN和NT-proBNP水平变化。结果:心衰患者的血清APN和NT-proBNP水平随着美国纽约心脏协会(NYHA)分级增加而明显升高;治疗6个月后,治疗组和对照组治疗总有效率分别为91.7%和75.0%,差异有统计学意义(P<0.01)。治疗后2组患者LVEDD和LVESD均缩小,LVEF明显提高,6-MWT明显增长,血清APN和NT-proBNP水平均降低,与对照组比较,治疗组以上指标改善更为显著,差异有统计学意义(P<0.05)。结论:芪苈强心胶囊可以显著降低冠心病合并心力衰竭患者的血清APN和NT-proBNP水平,明显改善心功能。 展开更多
关键词 芪苈强心胶囊 冠心病 心力衰竭 脂联素 心功能
下载PDF
芪苈强心胶囊对心气虚型慢性心力衰竭大鼠心肌腺苷酸含量的影响 被引量:56
19
作者 于春泉 李欣桐 +2 位作者 史芳 肖扬 王怡 《中国实验方剂学杂志》 CAS 北大核心 2012年第3期174-177,共4页
目的:观察芪苈强心胶囊对心气虚型慢性心衰大鼠缺血心肌中腺苷酸[三磷酸腺苷(ATP)、二磷酸腺苷(ADP)、一磷酸腺苷(AMP)]含量的影响。方法:采用结扎大鼠冠状动脉左前降支,心肌梗死8周后形成心气虚型慢性心力衰竭模型,随机分为假手术组、... 目的:观察芪苈强心胶囊对心气虚型慢性心衰大鼠缺血心肌中腺苷酸[三磷酸腺苷(ATP)、二磷酸腺苷(ADP)、一磷酸腺苷(AMP)]含量的影响。方法:采用结扎大鼠冠状动脉左前降支,心肌梗死8周后形成心气虚型慢性心力衰竭模型,随机分为假手术组、模型组、芪苈强心胶囊高、中、低(1.0,0.5,0.25 g.kg-1)剂量组、缬沙坦20 mg.kg-1组。连续给药4周后,利用高效液相色谱法,检测大鼠心脏缺血心肌中ATP,ADP,AMP含量,计算能荷。结果:模型组大鼠心肌组织中ATP,ADP,AMP含量分别由(8.96±2.68),(63.66±14.34),(201.6±66.80)mg.g-1下降至(5.75±1.19),(48.4±15.62),(133.4±54.53)mg.g-1,与假手术组比较具有显著差异(P<0.01),芪苈强心胶囊高剂量组能明显增加缺血心肌中ATP含量,提高能荷,与模型组比较有明显差异(P<0.05)。结论:芪苈强心胶囊可增加缺血心肌组织中腺苷酸含量,从而改善心肌梗死后心衰大鼠心肌能量代谢。 展开更多
关键词 芪苈强心胶囊 高能磷酸化合物 心力衰竭 心气虚证
原文传递
芪苈强心胶囊治疗慢性心力衰竭的系统评价 被引量:55
20
作者 刘春香 毛静远 +2 位作者 王贤良 侯雅竹 张川 《中成药》 CAS CSCD 北大核心 2010年第4期539-544,共6页
目的:评价芪苈强心胶囊(黄芪、附子、丹参、人参、葶苈子、红花、陈皮、泽泻、香加皮、玉竹和桂枝)治疗慢性心力衰竭(chronic heart failure,CHF)的临床疗效和安全性。方法:有7个随机临床对照研究纳入评价。结果:Meta分析结果显示,芪苈... 目的:评价芪苈强心胶囊(黄芪、附子、丹参、人参、葶苈子、红花、陈皮、泽泻、香加皮、玉竹和桂枝)治疗慢性心力衰竭(chronic heart failure,CHF)的临床疗效和安全性。方法:有7个随机临床对照研究纳入评价。结果:Meta分析结果显示,芪苈强心胶囊治疗组心力衰竭患者NYHA心功能分级相对危险度为1.21,95%的可信区间[1.08,1.36];6 min步行距离加权均数差为37.39,95%可信区间[22.58,52.20];提高左室射血分数(WMD=3.97[2.09,5.85])、减少左室舒张末期内径(WMD=2.81[1.41,4.22])、降低血浆B型钠尿肽(WMD=118.00[4.44,231.56])和脑钠肽前体N末端片段(WMD=476.90[371.26,582.54])水平及降低明尼苏达生活质量调查表计分(WMD=8.00[3.48,12.52]);对于左室舒张末容积和左室收缩末容积及心率和血压有降低趋势,结果仍需证实。此外,服用芪苈强心胶囊后,个别病例出现干咳、上腹部不适、胃胀等不良反应,均可耐受,并且与对照组比较无明显统计学差异。结论:芪苈强心胶囊对慢性心力衰竭患者心功能及生存质量的改善有效安全。 展开更多
关键词 芪苈强心胶囊 心力衰竭 系统评价
下载PDF
上一页 1 2 34 下一页 到第
使用帮助 返回顶部